GLAXOSMITHKLINE PLC ORD 25P found using the EPIC (LON:GSK) have now 20 analysts covering the company. The target price ranges between £19.00 and £14. meaning the average target price is £16.45. With the shares previous close at £12.24 this would imply there is a potential upside of 34.3%. There is a 50 day moving average of £12.92 and the 200 day MA is £13.87. The market capitalisation for the company is £63b. Visit the company website at: http://www.gsk.com
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; Novartis; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; and CureVac. The company also has an agreement with Vir Biotechnology, Inc for research and development of new therapies for influenza and other respiratory viruses. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
